Worldwide obesity has more than doubled since 1980 and most of the world’s population now live in countries where overweight and obesity kills more people than underweight. Obesity represents a major health challenge because it substantially increases the risk of diseases such as type 2 diabetes. In recent years, the prevalence of type 2 diabetes has soared worldwide with approximately 462 million individuals affected, corresponding to 6.28% of the world’s population (1).
Dr Harriet Schellekens and colleagues, at the APC Microbiome Ireland SFI Research Centre in UCC, identified Bifidobacterium longum APC1472 to be an important regulator of appetite and metabolism during laboratory studies (2). In a group of healthy people who were overweight or obese, this research shows that the novel bacterial strain Bifidobacterium Longum APC1472 reduced their fasting blood glucose levels and could normalise active levels of both ghrelin, a hormone that signals hunger, and the stress hormone cortisol, both of which are altered in obesity. While no effect was seen in reducing weight gain in humans, initial research showed that the bacterium reduced weight gain and fat depot size in obese mice.
“This study shows that B. longum APC1472 has potential to be developed as a valuable probiotic supplement to reduce blood glucose, which is important in the development of conditions such as type 2 diabetes”, according to Dr. Harriet Schellekens, leader of the research and joint senior author of the study. “This study is the first of its kind demonstrating the translation of a Bifidobacterium longum species, B. longum APC1472, from initial laboratory studies through pre-clinical studies to a human intervention study.”
It has been known for a long time that stress and obesity are linked. While stress can suppress appetite in the short-term, chronic stress is known to increase cortisol which increases appetite; hence the phrase “stress eating”. This research shows that B.Longum APC1472 plays an important role in keeping our hunger hormone, ghrelin, in check, and lowers our stress hormone, cortisol.
“This study was a real team effort and delivers important translational evidence that probiotic supplementation can indeed be useful in the fight against obesity,” said Prof John Cryan, joint senior-author of the study. “Moreover, the findings reinforce the concept of the link between the gut microbiome, metabolic disease and mental health, which is a growing area of research.”
Prof Timothy Dinan, Chief Investigator on the clinical part of the study, commented “The translational findings are solid and the modulation of cortisol awakening response, warrant further investigation of this B. longum APC1472 and its potential use as a psychobiotic to improve mental health”.
The research is published today in the prestigious Lancet journal, eBioMedicine, where Dr. Marcel van de Wouw and Dr. Cristina Torres-Fuentes are joint first authors. Original publication available here: “Bifidobacterium longum Counters the Effects of Obesity: Partial Successful Translation from Rodent to Human” Article (Clinical Trials).
The study was part funded by SFI Research Centre grant to APC Microbiome Ireland and a targeted project funded by Cremo SA. Atlantia Food Clinical Trials co-ordinated the human studies. 1. https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.201901433R 2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310804/
Innovations in Food (& Beverage) Technology is a quarterly magazine distributed globally both in Print and Digital formats. www.innovationsfood.com. Twitter: @Innovfoodtech. Instagram: @innovationsinfoodtechnology. Linkedin: www.linkedin.com/in/terry-prior52